-cyclodextrin – a weight loss agent?
Hansen, Lisbeth; Sørensen, Ditte; Ganesaratnam, Nirooshitha; Lumholdt, Ludmilla; Larsen, Kim Lambertsen

Publication date:
2011

Document Version
Early version, also known as pre-print

Link to publication from Aalborg University

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Users may download and print one copy of any publication from the public portal for the purpose of private study or research.

You may not further distribute the material or use it for any profit-making activity or commercial gain

You may freely distribute the URL identifying the publication in the public portal?

Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from vbn.aau.dk on: januar 11, 2019
In recent years, an alarming increase in overweight, obesity and the following diseases has been observed. Unfortunately, the current pharmacological treatments lack effectiveness or display a severe side effect profile. New improved drugs against overweight and obesity are therefore desirable. In USA and Canada, α-CD is marketed as a dietary fibre and used as a weight loss supplement (Mirafit FBCx™, Alpha-Fibe FBCx™). Moreover, a study has shown that adding α-CD to a diet resulted in greater weight loss compared to placebo and in another study α-CD prevented weight gain. The underlying mechanism for α-CDs possible weight loss ability is still to be accounted for. Findings from two studies show that α-CD can significantly lower the post-prandial plasma glucose response after a starch-rich meal. It is therefore hypothesized that α-CD inhibits the enzymatic degradation of starch, which this study aims to investigate further.

γ-cyclodextrin (γ-CD) and a starch solution was chosen as substrates. The hydrolysis by porcine pancreatic α-amylase (PPA) in the presence of α-CD was monitored at 37°C, pH 6.5. The degradation reactions were followed over time by quantification of the amount of reducing ends as maltose equivalents. The hydrolysis of γ-CD revealed that the presence of α-CD inhibited the enzymatic degradation in a dose-dependent manner. α-CD in a molar ratio of 0.2:1 (α-CD:γ-CD) was not sufficient to inhibit the degradation, whereas α-CD in a molar ratio of 1:1 showed some effect since the initial degradation rate decreased (from 4.6 mM/hour for the control (no α-CD present) to 4.0 mM/hour). In ratio 5:1 the degradation rate was almost 50% less (2.4 mM/hour). Lastly, the initial degradation rates in ratio 15:1 and 20:1 were only one third (1.2 mM/hour) of what was observed in the absence of α-CD. These results shows that α-CD is capable of inhibiting the enzymatic degradation of γ-CD considerably and that there might be an upper limit to the inhibitory effect.